199 related articles for article (PubMed ID: 35152144)
1. Combinatorial strategies to potentiate the efficacy of HDAC inhibitors in fusion-positive sarcomas.
Lanzi C; Cassinelli G
Biochem Pharmacol; 2022 Apr; 198():114944. PubMed ID: 35152144
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of ERK-EGR1-heparanase axis by HDAC inhibitors provides targets for rational therapeutic intervention in synovial sarcoma.
Lanzi C; Favini E; Dal Bo L; Tortoreto M; Arrighetti N; Zaffaroni N; Cassinelli G
J Exp Clin Cancer Res; 2021 Dec; 40(1):381. PubMed ID: 34857011
[TBL] [Abstract][Full Text] [Related]
3. Targeting the undruggable: exploiting neomorphic features of fusion oncoproteins in childhood sarcomas for innovative therapies.
Knott MML; Hölting TLB; Ohmura S; Kirchner T; Cidre-Aranaz F; Grünewald TGP
Cancer Metastasis Rev; 2019 Dec; 38(4):625-642. PubMed ID: 31970591
[TBL] [Abstract][Full Text] [Related]
4. Investigation of IGF2, Hedgehog and fusion gene expression profiles in pediatric sarcomas.
de Souza RR; Oliveira ID; del Giúdice Paniago M; Yaoita FH; Caran EM; Macedo CR; Petrilli AS; Abib Sde C; de Seixas Alves MT; de Toledo SR
Growth Horm IGF Res; 2014 Aug; 24(4):130-6. PubMed ID: 24846856
[TBL] [Abstract][Full Text] [Related]
5. The HDAC3-SMARCA4-miR-27a axis promotes expression of the
Bharathy N; Berlow NE; Wang E; Abraham J; Settelmeyer TP; Hooper JE; Svalina MN; Ishikawa Y; Zientek K; Bajwa Z; Goros MW; Hernandez BS; Wolff JE; Rudek MA; Xu L; Anders NM; Pal R; Harrold AP; Davies AM; Ashok A; Bushby D; Mancini M; Noakes C; Goodwin NC; Ordentlich P; Keck J; Hawkins DS; Rudzinski ER; Chatterjee B; Bächinger HP; Barr FG; Liddle J; Garcia BA; Mansoor A; Perkins TJ; Vakoc CR; Michalek JE; Keller C
Sci Signal; 2018 Nov; 11(557):. PubMed ID: 30459282
[TBL] [Abstract][Full Text] [Related]
6. KDM3A/Ets1 epigenetic axis contributes to PAX3/FOXO1-driven and independent disease-promoting gene expression in fusion-positive Rhabdomyosarcoma.
Sobral LM; Hicks HM; Parrish JK; McCann TS; Hsieh J; Goodspeed A; Costello JC; Black JC; Jedlicka P
Mol Oncol; 2020 Oct; 14(10):2471-2486. PubMed ID: 32697014
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma.
Lubieniecka JM; de Bruijn DR; Su L; van Dijk AH; Subramanian S; van de Rijn M; Poulin N; van Kessel AG; Nielsen TO
Cancer Res; 2008 Jun; 68(11):4303-10. PubMed ID: 18519690
[TBL] [Abstract][Full Text] [Related]
8. MS-275 (Entinostat) Promotes Radio-Sensitivity in PAX3-FOXO1 Rhabdomyosarcoma Cells.
Cassandri M; Pomella S; Rossetti A; Petragnano F; Milazzo L; Vulcano F; Camero S; Codenotti S; Cicchetti F; Maggio R; Festuccia C; Gravina GL; Fanzani A; Megiorni F; Catanoso M; Marchese C; Tombolini V; Locatelli F; Rota R; Marampon F
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639012
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic applications of histone deacetylase inhibitors in sarcoma.
Tang F; Choy E; Tu C; Hornicek F; Duan Z
Cancer Treat Rev; 2017 Sep; 59():33-45. PubMed ID: 28732326
[TBL] [Abstract][Full Text] [Related]
10. MicroRNAs in chromosomal translocation-associated solid tumors: learning from sarcomas.
Dela Cruz F; Matushansky I
Discov Med; 2011 Oct; 12(65):307-17. PubMed ID: 22031668
[TBL] [Abstract][Full Text] [Related]
11. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
[TBL] [Abstract][Full Text] [Related]
12. SS18-SSX, the Oncogenic Fusion Protein in Synovial Sarcoma, Is a Cellular Context-Dependent Epigenetic Modifier.
Tamaki S; Fukuta M; Sekiguchi K; Jin Y; Nagata S; Hayakawa K; Hineno S; Okamoto T; Watanabe M; Woltjen K; Ikeya M; Kato T; Toguchida J
PLoS One; 2015; 10(11):e0142991. PubMed ID: 26571495
[TBL] [Abstract][Full Text] [Related]
13. HDACs as an emerging target in endocrine tumors: a comprehensive review.
Klieser E; Neumayer B; Di Fazio P; Mayr C; Neureiter D; Kiesslich T
Expert Rev Endocrinol Metab; 2023 Mar; 18(2):143-154. PubMed ID: 36872882
[TBL] [Abstract][Full Text] [Related]
14. Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma.
Jerby-Arnon L; Neftel C; Shore ME; Weisman HR; Mathewson ND; McBride MJ; Haas B; Izar B; Volorio A; Boulay G; Cironi L; Richman AR; Broye LC; Gurski JM; Luo CC; Mylvaganam R; Nguyen L; Mei S; Melms JC; Georgescu C; Cohen O; Buendia-Buendia JE; Segerstolpe A; Sud M; Cuoco MS; Labes D; Gritsch S; Zollinger DR; Ortogero N; Beechem JM; Petur Nielsen G; Chebib I; Nguyen-Ngoc T; Montemurro M; Cote GM; Choy E; Letovanec I; Cherix S; Wagle N; Sorger PK; Haynes AB; Mullen JT; Stamenkovic I; Rivera MN; Kadoch C; Wucherpfennig KW; Rozenblatt-Rosen O; Suvà ML; Riggi N; Regev A
Nat Med; 2021 Feb; 27(2):289-300. PubMed ID: 33495604
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas-NCIC-CTG IND 200†.
Chu QS; Nielsen TO; Alcindor T; Gupta A; Endo M; Goytain A; Xu H; Verma S; Tozer R; Knowling M; Bramwell VB; Powers J; Seymour LK; Eisenhauer EA
Ann Oncol; 2015 May; 26(5):973-981. PubMed ID: 25632070
[TBL] [Abstract][Full Text] [Related]
16. A review of the therapeutic potential of histone deacetylase inhibitors in rhabdomyosarcoma.
Selim O; Song C; Kumar A; Phelan R; Singh A; Federman N
Front Oncol; 2023; 13():1244035. PubMed ID: 37664028
[TBL] [Abstract][Full Text] [Related]
17. Natural Agents-Mediated Targeting of Histone Deacetylases.
Farooqi AA; Naqvi SK; Perk AA; Yanar O; Tabassum S; Ahmad MS; Mansoor Q; Ashry MS; Ismail M; Naoum GE; Arafat WO
Arch Immunol Ther Exp (Warsz); 2018 Feb; 66(1):31-44. PubMed ID: 28852775
[TBL] [Abstract][Full Text] [Related]
18. Antitumor profile of the PI3K inhibitor ZSTK474 in human sarcoma cell lines.
Namatame N; Tamaki N; Yoshizawa Y; Okamura M; Nishimura Y; Yamazaki K; Tanaka M; Nakamura T; Semba K; Yamori T; Yaguchi SI; Dan S
Oncotarget; 2018 Oct; 9(80):35141-35161. PubMed ID: 30416685
[TBL] [Abstract][Full Text] [Related]
19. Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma.
Cheng L; Pandya PH; Liu E; Chandra P; Wang L; Murray ME; Carter J; Ferguson M; Saadatzadeh MR; Bijangi-Visheshsaraei K; Marshall M; Li L; Pollok KE; Renbarger JL
BMC Med Genomics; 2019 Jan; 12(Suppl 1):23. PubMed ID: 30704460
[TBL] [Abstract][Full Text] [Related]
20. Preclinical rationale for entinostat in embryonal rhabdomyosarcoma.
Bharathy N; Berlow NE; Wang E; Abraham J; Settelmeyer TP; Hooper JE; Svalina MN; Bajwa Z; Goros MW; Hernandez BS; Wolff JE; Pal R; Davies AM; Ashok A; Bushby D; Mancini M; Noakes C; Goodwin NC; Ordentlich P; Keck J; Hawkins DS; Rudzinski ER; Mansoor A; Perkins TJ; Vakoc CR; Michalek JE; Keller C
Skelet Muscle; 2019 May; 9(1):12. PubMed ID: 31113472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
